MedPath
HSA Approval

TAVNEOS HARD CAPSULE 10MG

SIN17150P

TAVNEOS HARD CAPSULE 10MG

TAVNEOS HARD CAPSULE 10MG

December 24, 2024

AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantAMGEN BIOTECHNOLOGY SINGAPORE PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

CAPSULE, GELATIN COATED

ORAL

Medical Information

L04AJ05

Manufacturer Information

AMGEN BIOTECHNOLOGY SINGAPORE PTE. LTD.

Patheon Pharmaceuticals Inc.

Active Ingredients

Avacopan

10mg

Avacopan

Documents

Package Inserts

Tavneos Hard Capsule PI.pdf

Approved: December 24, 2024

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

TAVNEOS HARD CAPSULE 10MG - HSA Approval | MedPath